Appili Therapeutics
Canada-based anti-infective pharmaceutical development company.
| CAD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (40 %) | - | - | (76 %) | 148 % | (88 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1302 %) | (2705 %) | - | (1691 %) | (2316 %) | (258 %) | 687 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1296 %) | (2720 %) | - | (1806 %) | (2766 %) | (457 %) | (2613 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1251 % | 1517 % | - | 1543 % | 1140 % | 705 % | 7300 % |
Source: Company filings or news article
Related Content
Appili Therapeutics, based in Nova Scotia, Canada, is dedicated to developing innovative drug programs to address unmet patient needs across a broad spectrum of infectious diseases. The company operates in the pharmaceutical and biotechnology market, focusing on creating solutions for serious global challenges in infectious diseases. Appili serves a diverse range of clients including patients, healthcare providers, and society at large. The business model revolves around active partnering and in-licensing efforts to expand clinical programs and accelerate commercialization. Revenue is generated through the development and commercialization of its drug programs, as well as through strategic partnerships and licensing agreements. The leadership team is highly skilled in advancing programs with significant potential, ensuring that the company remains at the forefront of infectious disease treatment innovation.
Keywords: infectious diseases, drug development, unmet needs, global health, biotechnology, pharmaceutical, commercialization, clinical programs, partnerships, innovation.